Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP12 | P39900 | 2/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650254 | 0.95 | MMP2 (0.53) | HSD17B10MMP2ADAMTS5PPARAMMP9 | |
| SCHEMBL4650209 | 0.93 | HSD17B10 (0.52) | HSD17B10MMP2MMP9MMP8MMP12 | |
| SCHEMBL4650952 | 0.88 | MMP2 (0.57) | HSD17B10MMP2ADAMTS5MMP9MMP8 | |
| SCHEMBL4650875 | 0.78 | PTPN1 (0.47) | HSD17B10MMP2MMP9 | |
| SCHEMBL6572379 | 0.78 | PTPN1 (0.54) | — | |
| SCHEMBL7612205 | 0.77 | TBXA2R (0.42) | HSD17B10MMP2PPARAMMP9MMP8 | |
| SCHEMBL6572881 | 0.76 | KLKB1 (0.53) | — | |
| SCHEMBL6572527 | 0.76 | MMP2 (0.51) | MMP2MMP9MMP8 | |
| SCHEMBL6572532 | 0.76 | MMP2 (0.51) | MMP2MMP9MMP8 | |
| SCHEMBL8110740 | 0.76 | PTPN1 (0.46) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | claimed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | claimed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | HSD17B10 1935/4885MMP2 1609/4885ADAMTS5 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.